Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


1.		AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				16 and over				Other				MK1-192 NCT00180128


2.		Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				LAP-R2007 NCT00504764


3.		Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 60				Other				AMLSG07-04 NCT00151242

Last Modified: 4/28/2008 First Published: 5/21/2007


4.		Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and under				Other				UCHM-AML-BFM-2004 UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004


5.		Acute Promyelocytic Leukemia 2006 (APL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				P050604 NCT00378365

Last Modified: 6/5/2007 First Published: 5/23/2007


6.		Phase III Randomized Study of Arsenic Trioxide and Tretinoin Versus Combination Chemotherapy Comprising Tretinoin, Idarubicin, Mitoxantrone Hydrochloride, Methotrexate, and Mercaptopurine for Patients With Newly Diagnosed Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				GIMEMA-DSL-APL0406 EUDRACT-2006-006188-22, APL0406, EU-20725, NCT00482833

Last Modified: 1/14/2009 First Published: 6/21/2007


7.		Phase III Randomized Study of Induction and Consolidation Combination Chemotherapy With or Without Gemtuzumab Ozogamicin Followed By Maintenance Therapy Comprising Tretinoin, Mercaptopurine, and Methotrexate Versus Observation in Patients With Previously Untreated Low- or Intermediate-Risk Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				SWOG-S0521 S0521, NCT00492856


8.		Differentiation Induction in Acute Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				REK-Vestnr21503 NCT00175812

Last Modified: 10/12/2006 First Published: 9/23/2006


9.		Phase I/II Study of Decitabine and Tretinoin in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MSKCC-06054 NCT00382200


10.		5-Azacytidine Valproic Acid and ATRA in AML and High Risk MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				P050202 NCT00339196

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute